Published in J Clin Oncol on February 01, 1986
Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy. Breast Cancer Res (2003) 1.26
Systemic therapy of advanced breast cancer. Drugs (1992) 0.99
LHRH analogues in breast cancer: clever, but do we need them? Br J Cancer (1991) 0.84
Bone loss and the aromatase inhibitors. Br J Cancer (2005) 0.84
Reversible control of oestradiol-stimulated growth of MCF-7 tumours by tamoxifen in the athymic mouse. Br J Cancer (1991) 0.82
Current approaches to the management of Her2-negative metastatic breast cancer. Breast Cancer Res (2012) 0.77
LHRH analogues and breast cancer. Br J Cancer (1991) 0.75
Clinical Implications of the Progression-Free Survival Endpoint for Treatment of Hormone Receptor-Positive Advanced Breast Cancer. Oncologist (2016) 0.75
Luteal versus follicular phase surgical oophorectomy plus tamoxifen in premenopausal women with metastatic hormone receptor-positive breast cancer. Eur J Cancer (2016) 0.75
Current Medical Treatment of Patients with Non-Colorectal Liver Metastases: Primary Tumor Breast Cancer. Viszeralmedizin (2015) 0.75
Adjuvant therapy for operable breast cancer; more answers, new questions. Br J Cancer (1995) 0.75
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol (2009) 9.18
Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med (1991) 7.21
Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science (1994) 4.50
Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med (2000) 4.50
Field trials of the Baby Check score card: mothers scoring their babies at home. Arch Dis Child (1991) 4.31
Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol (1989) 4.03
Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol (1989) 3.44
Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med (1994) 3.29
Centrosome hypertrophy in human breast tumors: implications for genomic stability and cell polarity. Proc Natl Acad Sci U S A (1998) 3.23
Primary breast sarcoma: clinicopathologic series from the Mayo Clinic and review of the literature. Br J Cancer (2004) 3.10
Activation of macrophages for destruction of Francisella tularensis: identification of cytokines, effector cells, and effector molecules. Infect Immun (1992) 3.09
Postchemotherapy rheumatism. J Clin Oncol (1993) 3.01
17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K, and SIGma1B genes. Cancer Res (2000) 2.81
Field trials of the Baby Check score card in hospital. Arch Dis Child (1991) 2.64
Diversity of sulfate-reducing bacteria in oxic and anoxic regions of a microbial mat characterized by comparative analysis of dissimilatory sulfite reductase genes. Appl Environ Microbiol (1999) 2.55
Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol (1998) 2.51
Increased HER2 with U.S. Food and Drug Administration-approved antibody. J Clin Oncol (1999) 2.48
American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol (2000) 2.39
Field trials of the Baby Check score card in general practice. Arch Dis Child (1991) 2.39
Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial. Ann Intern Med (1991) 2.37
Metaplastic breast cancer: prognosis and response to systemic therapy. Ann Oncol (1999) 2.12
Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res (2000) 1.98
Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol (1991) 1.93
Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol (1994) 1.93
Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst (1990) 1.92
Induction of nitric oxide synthase protects against malaria in mice exposed to irradiated Plasmodium berghei infected mosquitoes: involvement of interferon gamma and CD8+ T cells. J Exp Med (1994) 1.83
Unexpected population distribution in a microbial mat community: sulfate-reducing bacteria localized to the highly oxic chemocline in contrast to a eukaryotic preference for anoxia. Appl Environ Microbiol (1999) 1.75
Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer. J Clin Oncol (1990) 1.74
Life and death of an intracellular pathogen: Francisella tularensis and the macrophage. Immunol Ser (1994) 1.73
IFN-gamma inhibits development of Plasmodium berghei exoerythrocytic stages in hepatocytes by an L-arginine-dependent effector mechanism. J Immunol (1991) 1.73
Differential susceptibility of activated macrophage cytotoxic effector reactions to the suppressive effects of transforming growth factor-beta 1. J Immunol (1991) 1.71
Platelet activating factor (PAF) involvement in endotoxin-induced hypotension in rats. Studies with PAF-receptor antagonist kadsurenone. Biochem Biophys Res Commun (1985) 1.71
Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med (1981) 1.70
Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplant (2001) 1.67
Prospective evaluation of prognostic variables from patient-completed questionnaires. North Central Cancer Treatment Group. J Clin Oncol (1994) 1.67
A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. J Natl Cancer Inst (1996) 1.58
Malignant lymphoma of the spleen. A review of 49 cases in which the diagnosis was made at splenectomy. Cancer (1966) 1.54
A comparative evaluation of marketed analgesic drugs. N Engl J Med (1972) 1.50
Recognition of E-cadherin on epithelial cells by the mucosal T cell integrin alpha M290 beta 7 (alpha E beta 7). Eur J Immunol (1995) 1.47
Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: an analysis of two intergroup trials. J Clin Oncol (1996) 1.43
Impact of surgical and pathologic variables in rectal cancer: a United States community and cooperative group report. J Clin Oncol (2001) 1.42
Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol (1998) 1.42
Policies for study monitoring and interim reporting of results. J Clin Oncol (1987) 1.41
Breast conservation therapy for invasive breast cancer: a review of prior trials and the Mayo Clinic experience. Mayo Clin Proc (1994) 1.38
Bolus versus infusion regimens of etoposide and cisplatin in treatment of non-small cell lung cancer: a study of the North Central Cancer Treatment group. J Natl Cancer Inst (1990) 1.37
Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg (1990) 1.34
Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol (1997) 1.31
The significance of anti-S sensitization in pregnancy. Clin Lab Haematol (1990) 1.30
A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma. J Clin Oncol (1985) 1.29
2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev (2000) 1.28
Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Res Treat (1999) 1.27
Molecular markers in male breast carcinoma. Cancer (1998) 1.26
Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma. J Neurosurg (1995) 1.25
Phase II clinical trial of isophosphamide (NSC-109724) in patients with advances breast cancer. Cancer Chemother Rep (1975) 1.25
The hyaluronate receptor is identical to a glycoprotein of Mr 85,000 (gp85) as shown by a monoclonal antibody that interferes with binding activity. J Biol Chem (1987) 1.24
Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. N Engl J Med (1996) 1.24
Characterization of a platelet-activating factor receptor antagonist isolated from haifenteng (Piper futokadsura): specific inhibition of in vitro and in vivo platelet-activating factor-induced effects. Proc Natl Acad Sci U S A (1985) 1.24
Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion. A study of the Mayo Clinic and the North Central Cancer Treatment Group. Arch Surg (1990) 1.21
Inhibition of hydroxymethylglutaryl-coenzyme A synthase by L-659,699. Proc Natl Acad Sci U S A (1987) 1.21
Hemolytic assay of the ninth complement complement component: elevation and depletion in rheumatic diseases. J Exp Med (1971) 1.20
Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer (1989) 1.18
Biogeochemical cycling and microbial diversity in the thrombolitic microbialites of Highborne Cay, Bahamas. Geobiology (2010) 1.15
Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol (1999) 1.15
Pericardial effusion in women with breast cancer. Cancer (1987) 1.13
Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis. Cancer (1991) 1.13
External radiation exposure and mortality in a cohort of uranium processing workers. Am J Epidemiol (2000) 1.13
Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analyses. Cancer (1987) 1.12
Relief of pain by oral medications. A controlled evaluation of analgesic combinations. JAMA (1974) 1.12
Co-localization of inducible-nitric oxide synthase and Plasmodium berghei in hepatocytes from rats immunized with irradiated sporozoites. J Immunol (1995) 1.12
A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer (1990) 1.12
A simple stratification factor prognostic for survival in advanced cancer: the good/bad/uncertain index. J Clin Oncol (2001) 1.12
Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group. J Clin Oncol (1994) 1.09
The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol (2005) 1.08
The bone marrow examination in breast cancer: diagnostic considerations and clinical usefulness. Cancer (1978) 1.08
Tissue factor pathway inhibitor inhibits endothelial cell proliferation via association with the very low density lipoprotein receptor. J Biol Chem (2001) 1.07
Studies on transcriptional regulation of the mucosal T-cell integrin alphaEbeta7 (CD103). Immunology (2001) 1.06
Treatment of testicular cancer. Annu Rev Med (1975) 1.06
Confidence intervals following group sequential tests. Control Clin Trials (1986) 1.06
Identification of a binding site for integrin alphaEbeta7 in the N-terminal domain of E-cadherin. J Biol Chem (1996) 1.05
Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. Ann Oncol (2012) 1.05
Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol (1995) 1.05
Considerations for monitoring and evaluating treatment effects in clinical trials. Control Clin Trials (1984) 1.05